eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Short Interest Up 650.0% in June

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) saw a significant increase in short interest during the month of June. As of June 30th, there was short interest totalling 687,000 shares, an increase of 650.0% from the June 15th total of 91,600 shares. Currently, 16.8% of the shares of the company are sold short. Based on an average daily trading volume, of 645,000 shares, the short-interest ratio is presently 1.1 days.

eFFECTOR Therapeutics Stock Up 19.6 %

eFFECTOR Therapeutics stock traded up $0.01 during mid-day trading on Friday, hitting $0.08. The company’s stock had a trading volume of 101,046 shares, compared to its average volume of 480,155. The stock has a market capitalization of $376,470.00, a P/E ratio of 0.00 and a beta of 0.62. eFFECTOR Therapeutics has a twelve month low of $0.03 and a twelve month high of $21.50. The stock’s fifty day moving average price is $1.24 and its two-hundred day moving average price is $6.87.

eFFECTOR Therapeutics (NASDAQ:EFTR) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.17) by $0.01. Equities analysts expect that eFFECTOR Therapeutics will post -5.63 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $24.00 price target on shares of eFFECTOR Therapeutics in a report on Thursday, March 28th.

Hedge Funds Weigh In On eFFECTOR Therapeutics

A hedge fund recently bought a new stake in eFFECTOR Therapeutics stock. StemPoint Capital LP purchased a new stake in shares of eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 132,793 shares of the company’s stock, valued at approximately $1,911,000. StemPoint Capital LP owned approximately 3.60% of eFFECTOR Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 57.67% of the company’s stock.

About eFFECTOR Therapeutics

eFFECTOR Therapeutics, Inc, a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer.